Related Experiment Video
Updated: Aug 26, 2025
14:39
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
Published on: November 4, 2010
32.0K
Current Biologics in Asthma Treatment
Donya Imanirad1, Farnaz Tabatabaian2
1Department of Allergy, Immunology, Morsani College of Medicine, University of South Florida, Tampa, Florida.
Seminars in Respiratory and Critical Care Medicine
|October 11, 2022
Summary
Severe asthma significantly impacts quality of life and healthcare costs. Monoclonal antibodies offer new treatments, with current biologics targeting T2-high inflammation, while T2-low inflammation therapies are emerging.
Area of Science:
- Pulmonology and immunology
- Allergy and clinical immunology
Background:
- Uncontrolled and severe asthma leads to significant quality of life impairments and substantial healthcare burdens.
- Monoclonal antibodies represent a key advancement in managing moderate-to-severe asthma unresponsive to conventional therapies.
- Current FDA-approved biologics primarily target T2-high inflammatory pathways in asthma.
Purpose of the Study:
- To review the current understanding of T2 inflammation in asthma.
- To discuss biologics approved for moderate-to-severe asthma.
- To highlight emerging therapeutics for T2-low asthma.
Main Methods:
- Literature review of current asthma pathogenesis.
- Analysis of Food and Drug Administration (FDA)-approved biologic therapies.
- Discussion of novel therapeutic targets in asthma.
Main Results:
- The majority of approved biologics target T2-high inflammation.
- Growing knowledge of asthma pathogenesis reveals novel therapeutic targets.
- Development of novel therapeutics for T2-low inflammation is ongoing.
Conclusions:
- Biologics targeting T2-high inflammation are established treatments for severe asthma.
- Future asthma management will likely include therapies for T2-low inflammation.
- Continued research into asthma pathogenesis is crucial for developing new treatments.
Related Concept Videos
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
405
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
405
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
363
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
363
01:30Asthma-IV: Diagnostic and Management
2.6K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.6K
01:19Antiasthma Drugs: Leukotriene Modifiers
417
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
417
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
347
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
347
01:17Drugs Used in Lower Respiratory Disorders: Overview
555
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
555